January 9, 2019 11:33 AM EST

Anti-aging startup Unity dives into eye diseases as partnership with Ascentage bears fruit

Amber Tong

After more than two years of hunting for treasure in Ascentage’s library of cell death regulating compounds, Unity Biotechnology thinks it has found a winner …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Anti-aging startup Unity dives into eye diseases as partnership with Ascentage bears fruit

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

An­ti-ag­ing start­up Uni­ty dives in­to eye dis­eases as part­ner­ship with As­cen­t­age bears fruit

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Anti-aging startup Unity dives into eye diseases as partnership with Ascentage bears fruit

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Food allergy biotech Alladapt closes after Phase 3 talks with FDA